Table 3.
Multivariate analysis of prognostic factors for OS in HCC patients with MVI.
| Variables | Multivariate analyses | |||
|---|---|---|---|---|
| HR | 95%CI | P | ||
| Age (year) | <65 | 1 | Reference | – |
| ≥65 | 1.216 | 0.784–1.885 | .382 | |
| Gender | Male | 1 | Reference | – |
| Female | 0.892 | 0.777–1.024 | .105 | |
| Tumor size | ≤10 cm | 1 | Reference | – |
| >10 cm | 1.394 | 1.100–1.767 | .006 | |
| Tumor number | Single | 1 | Reference | – |
| Multiple | 1.307 | 0.894–1.911 | .167 | |
| PVTT | Vp2 | 1 | Reference | – |
| Vp3 | 1.032 | 1.007–1.058 | .013 | |
| Vp4 | 2.015 | 1.191–3.409 | .009 | |
| HVTT | No | 1 | Reference | – |
| Yes | 1.472 | 1.045–2.074 | .027 | |
| T stage | T3b | 1 | Reference | – |
| T4 | 1.028 | 0.987–1.071 | .186 | |
| N stage | N0 | 1 | Reference | – |
| N1 | 1.013 | 0.990–1.037 | .275 | |
| Underlying disease | No | 1 | Reference | – |
| HBV | 1.005 | 0.997–1.013 | .218 | |
| HCV | 1.228 | 0.797–1.893 | .352 | |
| AFP | ≤400 ng/L | 1 | Reference | – |
| >400 ng/L | 1.513 | 1.114–2.055 | .008 | |
| ECOG | 0–1 | 1 | Reference | – |
| >1 | 1.029 | 0.993–1.066 | .117 | |
| Treatment | TACE plus IMRT | 1 | Reference | – |
| TACE plus IMRT plus sorafenib | 0.488 | 0.277–0.860 | .013 | |
AFP = alpha-fetoprotein, ECOG = Eastern Cooperative Oncology Group, HBV = hepatitis B virus, HCV = hepatitis C virus, HVTT = hepatic vein tumor thrombosis, IMRT = intensity-modulated radiotherapy, PVTT = portal vein tumor thrombosis, TACE = transcatheter arterial chemoembolization.